SyntheticMR Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de SyntheticMR han disminuido a una tasa media anual de -6.4%, mientras que en la industria Healthcare Services los beneficios crecieron en un 16.1% anualmente. Los ingresos han ido creciendo a una tasa media de 13.2% al año. La rentabilidad financiera de SyntheticMR es de 8.6%, y sus márgenes netos son de 10.6%.

Información clave

-6.4%

Tasa de crecimiento de los beneficios

-7.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	-11.7%
Tasa de crecimiento de los ingresos	13.2%
Rentabilidad financiera	8.6%
Margen neto	10.6%
Próxima actualización de resultados	21 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero SyntheticMR. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NGM:SYNT Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	94	10	43
30 Sep 23	85	6	42
30 Jun 23	83	6	40
31 Mar 23	80	7	37
31 Dec 22	74	6	35
30 Sep 22	71	8	33
30 Jun 22	65	7	31
31 Mar 22	58	2	30
31 Dec 21	63	8	30
30 Sep 21	60	8	29
30 Jun 21	57	5	29
31 Mar 21	55	3	29
31 Dec 20	52	1	27
30 Sep 20	47	-6	29
30 Jun 20	48	-3	27
31 Mar 20	51	2	26
31 Dec 19	48	4	24
30 Sep 19	53	12	23
30 Jun 19	52	13	22
31 Mar 19	50	14	20
31 Dec 18	51	15	19
30 Sep 18	49	14	18
30 Jun 18	45	12	17
31 Mar 18	39	8	16
31 Dec 17	38	8	16
30 Sep 17	34	8	15
30 Jun 17	30	7	13
31 Mar 17	28	6	12
31 Dec 16	22	2	12
30 Sep 16	15	1	9
30 Jun 16	14	4	8
31 Mar 16	11	1	9
31 Dec 15	9	0	9
30 Sep 15	7	-4	10
30 Jun 15	5	-9	11
31 Mar 15	5	-8	10
31 Dec 14	4	-7	9
30 Sep 14	5	-6	9
30 Jun 14	5	-5	8
31 Mar 14	5	-5	7
31 Dec 13	4	-5	7
30 Sep 13	4	-4	6

Ingresos de calidad: SYNT tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio (10.6%) de SYNT son superiores a los del año pasado (8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de SYNT han disminuido en un 6.4% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de SYNT en el último año (70.3%) supera su media de 5 años (-6.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de SYNT en el último año (70.3%) superó al de la industria Healthcare Services 70.3%.

SyntheticMR Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Recent updates

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Third quarter 2021 earnings released: EPS kr0.06 (vs kr0.004 loss in 3Q 2020)

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyntheticMR Signs Global Agreement with Philips to include SyntheticMR's Solution in Third Party Product Catalogue

Second quarter 2021 earnings released

Consensus EPS estimates fall to kr0.32

Price target decreased to kr44.00

Desglose de ingresos y gastos
Beta